Abstracts

Thursday, October 15, 2015 – Poster Session 1 (P1)

 

GCOS2015-OA-001

Bidirectional cross-regulation between ERbB2 and β-adrenergic signaling pathways

Presenting Author: Kathy Gabrielson, MD

 

GCOS2015-P1-001

Novel cardiac MRI model in anthracycline-induced cardiotoxicity: Can imaging and circulating biomarkers help identify patients at risk?

Presenting Author: Laura Cove-Smith, MD

 

GCOS2015-P1-002

Visnagin Protects Against Doxorubicin-Induced Cardiomyopathy Through Modulation of Mitochrondrial Malate Dehydrogenase

Presenting Author: Aarti Asnani, MD

 

GCOS2015-P1-003

Cardiac Death in Randomised Anthracycline trials: A New Published-Data Meta-analysis

Presenting Author: Amanda Kerr, DPhil Student

 

GCOS2015-P1-004

Validation of a Novel Trastuzumab-Induced Cardiotoxicity Prediction Tool for Breast Cancer Patients

Presenting Author: Jeffrey Sulpher, MD

 

GCOS2015-P1-005

Hospitalisation and death due to cardiovascular disease after early stage breast cancer

Presenting Author: Husam Abdel-Qadir, MD

 

GCOS2015-P1-006

The role of mitochondria-associated membrane proteins in doxorubicin-induced cardiotoxicity in murine myocytes

Presenting Author: Guo Hua Li

 

GCOS2015-P1-007

Dexrazoxane is associated with better preservation of long-term cardiac function in anthracycline-treated pediatric cancer survivors

Presenting Author: George Manase, BSc

 

GCOS2015-P1-008

Prediction and early detection of anthracycline related cardiotoxicity using cardiac biomarkers

Presenting Author: Patrick Stevens, MD

 

GCOS2015-P1-009

Optimizing cardiotoxicity monitoring protocols: less but not worst

Presenting Author: Teresa López Fernández, MD

 

GCOS2015-P1-010

Surgery for Cancer – The Prediction of Perioperative Risk Using Plasma Troponin in the VISION study

Presenting Author: Darryl Leong, MD

 

GCOS2015-P1-011

Radical PC

1.The Role of Androgen Deprivation Therapy in CArdiovascular Disease – A Longitudinal Prostate Cancer Study (RADICAL PC1)

2. A RAndomizeD Intervention for CArdiovascular and Lifestyle Risk Factors in Prostate Cancer Patients (RADICAL PC2)

Presenting Author: Darryl Leong, MD

 

GCOS2015-P1-012

Impaired left ventricular ejection fraction and global longitudinal strain in breast cancer HER2+ patients treated with doxorubicin, taxanes and trastuzumab. One year follow up.

Presenting Author: Ariane Macedo, MD

 

GCOS2015-P1-013

Acute onset of severe heart failure in a 42 year-old woman treated with trastuzumab

Presenting Author: David Sheps, MD

 

GCOS2015-P1-014

Referral Patterns and Diagnoses from a Newly Developed Cardio-Oncology Clinic

Presenting Author: Roohi Ismail-Khan, MD

 

GCOS2015-P1-015

Major cardiovascular events: A calculated risk in cancer survivors?

Presenting Author: Melanie Keats, PhD

 

GCOS2015-P1-016

Cardiac Effects of Combination Trastuzumab and Pertuzumab Therapy

Presenting Author: Wendy Bottinor, MD

 

GCOS2015-P1-017

Ventricular Tachycardia and Myocardial Fibrosis Diagnosed After Treatment with Pembrolizumab and Ipilimumab

Presenting Author: Marianne Krive, DO

 

GCOS2015-P1-018

Assessment of subclinical treatment-induced cardiotoxicity using left ejection function in breast cancer patients during trastuzumab treatment

Presenting Author: Olexiy Aseyev, MD

 

GCOS2015-P1-019

Reproducibility of Left Ventricle Contouring Methods in Patients Undergoing CMR-based Surveillance for Chemotherapy Induced Cardiotoxicity

Presenting Author: Louis Kolman, MD

 

GCOS2015-P1-020

Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: a meta-analysis of Phase III randomized controlled trials

Presenting Author: Husam Abdel-Qadir, MD

 

GCOS2015-P1-021

Resting heart rate and blood pressure changes during and after chemotherapy for breast cancer concurrent to exercise training

Presenting Author: Amy Kirkham, PhD Candidate

 

GCOS2015-P1-022

Cardiovascular Risk & Communication among Breast Cancer Survivors

Presenting Author: Allison Christian, MD

 

GCOS2015-P1-023

Incidence of chemotherapy induced left ventricular dysfunction varies depending on the definition

Presenting Author: Amy Erica Lin, MD

 

GCOS2015-P1-024

Comparison of Oncologic and Cardiovascular Outcomes Associated with Continuation vs. Interruption of Adjuvant Trastuzumab Therapy Complicated by the Development of Mild Left Ventricular Dysfunction

Presenting Author: Margot Davis, MD

 

GCOS2015-P1-025

The ECOG-ACRIN Cardiotoxicity Working Group

Presenting Author: Anne ONeill

 

GCOS2015-P1-026

The development of an international cardio-oncology registry: a work in progress

Presenting Author: Olexiy Aseyev, MD

 

GCOS2015-P1-027

Identifying the incidence of trastuzumab-induced cardiotoxicity at St. Michael’s Hospital

Presenting Author: Grace Tang

 

GCOS2015-P1-028

Presenting Author: K. Lynne Quinn, RN

 

Friday, October 16, 2015 – Poster Session 2 (P2)

 

GCOS2015-P2-001

An advance practice nursing initiative to improve cardio-oncology inpatient care

Presenting Author: Darlene Grantham, Oncology Nurse Specialist

 

GCOS2015-P2-002

Carvedilol as treatment for asymptomatic decline in cardiac function due to trastuzumab toxicity

Presenting Author: Abigail Wenzlick, BS

 

GCOS2015-P2-003

Treatment of mekinist-associated cardiotoxicity in a patient with metastatic melanoma

Presenting Author: Abigail Wenzlick, BS

 

GCOS2015-P2-004

Cardiovascular disease an emerging threat to patients with cancer?

Presenting Author: Darryl Leong, MD

 

GCOS2015-P2-005

A systematic review and meta-analysis of blood biomarkers for the identification of chemotherapy cardiotoxicity

Presenting Author: Darryl Leong, MD

 

GCOS2015-P2-006

Feasibility of a clinical trail of ACE inhibitor therapy to ameliorate anthracycline cardiotoxicity in childhood cancer survivors

Presenting Author: Paul Nathan, MD

 

GCOS2015-P2-007

Lack of prognostic significance using biomarkers in AL cardiac amyloid

Presenting Author: Johana Almansa, MSN, ANP-BC, CHFN

 

GCOS2015-P2-008

Echocardiographic evaluation in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitor. Long-term follow up.

Presenting Author: Nazanin Aghel, MD

 

GCOS2015-P2-009

Myocardial strain is lower in anthracycline-treated paediatric cancer survivors

Presenting Author: Corry Simmons, BA

 

GCOS2015-P2-010

The utility of cardiac biomarkers during anthracycline chemotherapy for the detection of cardiac events: Comparison left ventricular ejection fraction

Presenting Author: Patrick Stevens, MD

 

GCOS2015-P2-011

Influence of papillary muscle on LV ejection fraction measurement in patients undergoing CMR-based surveillance for chemotherapy induced cardiotoxicity

Presenting Author: Louis Kolman, MD

 

GCOS2015-P2-012

Prevalence of cardiovascular disease in cancer patients. CARDIOTOX Registry

Presenting Author: Teresa Lopez Fernandez, MD

 

GCOS2015-P2-013

A Bayesian network meta-analysis of protective therapies against anthracycline-related cardiotoxicity

Presenting Author: Husam Abdel-Qadir, MD

 

GCOS2015-P2-014

Prognostic value of global longitudinal strain in patients with AL amyloidosis undergoing autologous stem cell transplantation

Presenting Author: Shawn Pun, MD

 

GCOS2015-P2-015

Successful reduction in standard anti platelet dose in acute coronary syndrome and myelodysplastic syndrome complicated by acute myelogenous leukaemia transformation and thrombocytopenia

Presenting Author: Mohamed Elamin, MD

 

GCOS2015-P2-016

Diastolic dysfunction in amyloidosis cardiomyopathy vs heart failure with preserved ejection fraction

Presenting Author: Jose Nativi-Nicolau, MD

 

GCOS2015-P2-017

Chemotherapy induced right ventricle dysfunction in women with breast cancer receiving adjuvant HER2+ targeted cancer treatment

Presenting Author: Amy Erica Lin, MD